20th week of 2020 patent applcation highlights part 9 |
Patent application number | Title | Published |
20200147000 | USE OF TAPINAROF FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS - Topical compositions and methods for using topical compositions comprising tapinarof to treat chronic mild to moderate plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2. | 2020-05-14 |
20200147001 | USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITIS - Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. | 2020-05-14 |
20200147004 | PROMOTION OF LYMPHATIC FUNCTION - The present invention refers to lipophilic extracts of members of the Iridaceae family, such as | 2020-05-14 |
20200147005 | METHOD OF TREATING MAJOR DEPRESSIVE DISORDER - The present invention provides a method for safe and efficacious administration of esketamine. | 2020-05-14 |
20200147006 | METHOD OF TREATING POST-TRAUMATIC STRESS DISORDER - The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD. | 2020-05-14 |
20200147007 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE - Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels. | 2020-05-14 |
20200147008 | BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2020-05-14 |
20200147009 | PETROLATUM-BASED COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSIS - Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier. The one or more anti-fungal agents may include, for example, terbinafine HCl, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof. | 2020-05-14 |
20200147010 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO SUPPRESS TUMOR METASTASES - The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein. | 2020-05-14 |
20200147011 | PETROLATUM-BASED PHMB COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSIS - Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB), and/or chlorhexidine (CHG) in a petrolatum carrier. | 2020-05-14 |
20200147012 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES - This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof, e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same. | 2020-05-14 |
20200147013 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES - This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same. | 2020-05-14 |
20200147014 | NOVEL TREATMENT FOR HOT FLUSHES - Disclosed herein are methods for treating hot flushes in a subject. In one embodiment, treating hot flushes includes administering to a subject in need of such treatment, a therapeutically effective amount of a transient receptor potential channel (TRP channel) blocker or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for amelioration, alleviation, or prevention of the thermal discomfort in hot flushes, comprising: selecting a subject in need of treatment for hot flushes, administering to the subject a therapeutically effective amount of a TRP channel blocker, such as a TRPV1 blocker, or a pharmaceutically acceptable salt thereof. | 2020-05-14 |
20200147015 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES - The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent. | 2020-05-14 |
20200147016 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF - A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example. | 2020-05-14 |
20200147017 | Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators - Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof. | 2020-05-14 |
20200147018 | COMPOSITIONS AND METHODS FOR INDUCING INTESTINAL STEM CELL REGENERATION - The present invention provides compositions comprising β-hydroxybutyrate, cyclic or linear β-hydroxybutyrate oligomers, and/or β-hydroxybutyrate ester derivatives, or pharmaceutically-acceptable salts thereof. In various embodiments, the compositions are encapsulated by nanoparticles, such as nanoparticles comprising, e.g., poly(lactic-co-glycolic acid). In additional embodiments, the invention provides methods of using such compositions to induce intestinal stem cell regeneration and/or treat radiation-induced intestinal damage in a subject. | 2020-05-14 |
20200147019 | GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS - Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective. | 2020-05-14 |
20200147020 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY - Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent. | 2020-05-14 |
20200147021 | BLOOD FLOW IMPROVER - Provided is a blood flow improver which is safe and has a mild action. The blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient. | 2020-05-14 |
20200147022 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES - Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone. | 2020-05-14 |
20200147023 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES - Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone. | 2020-05-14 |
20200147024 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES - Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone. | 2020-05-14 |
20200147025 | COMPOSITION FOR USE IN THE TREATMENT OF EPILEPSY - A composition comprising a decanoic acid to octanoic acid ratio of 70:30 to 90:10 wt/wt for use in treating epilepsy or controlling epileptic seizures. | 2020-05-14 |
20200147026 | DIAGNOSIS OF DIABETES BY DETECTING AGGREGATED AMYLIN IN ERYTHROCYTES - The presently-disclosed subject matter generally relates to methods for detecting the presence of amylin in a patient's erythrocytes, determining the risk for the development of prediabetes, type-2 diabetes or comorbidities thereof, and methods of treating said diseases and risks. | 2020-05-14 |
20200147027 | BETAINE FOR THE PREVENTION OF OBESITY - The present invention provides a betaine compound for use in the prevention of obesity, excessive fat accumulation and/or metabolic disorders associated with either of the foregoing in a subject, wherein the prevention comprises administering the betaine compound directly to the subject during infancy or, alternatively, to the subject's mother during breast-feeding. Also provided are compositions comprising an effective amount of betaine compound together with one or more pharmaceutically or edible acceptable excipients and/or carriers for this use. | 2020-05-14 |
20200147028 | TREATMENT OF RESPIRATORY INFECTION WITH A TLR2 AGONIST - The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and/or treatment of rhinovirus infection and the prevention and/or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier. | 2020-05-14 |
20200147029 | NANOSTRUCTURED AND BIOCOMPATIBLE BIOCATALYSTS FOR USE IN CANCER TREATMENT - Nanostructured and biocompatible biocatalysts an organic ligand either linear or branched to Pt, Cu, or Fe-based compounds, in II, III or IV oxidation state, having cytotoxic activity for use in the treatment of cancer in animals or humans. | 2020-05-14 |
20200147030 | COMPOSITIONS, METHODS, SYSTEMS AND/OR KITS FOR PREVENTING AND/OR TREATING NEOPLASMS - Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one of quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone. | 2020-05-14 |
20200147031 | METHODS OF TREATING AUTOIMMUNE MICROVASULAR DISORDERS - Methods of treating autoimmune microvascular conditions using diosmin or diosmetin are described, particularly the treatment of digital ulcers in systemic sclerosis. | 2020-05-14 |
20200147032 | DIHYDROMYRICETIN HOT MELT EXTRUSION FORMULATIONS AND METHODS FOR FORMING THEM - Compositions including dihydromyricetin (DHM) and methods for forming them through hot melt extrusion. | 2020-05-14 |
20200147033 | NUTRACEUTICAL COMPOSITION FOR PDE4 INHIBITION, ENHANCED DOPAMINE METABOLISM AND LONG TERM POTENTIATION - A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B | 2020-05-14 |
20200147034 | CPC DISTRIBUTION CHROMATOGRAPHY OF CANNABINOIDS - The invention relates to cannabinoids and their isolation and purification and to obtaining them by means of centrifugal partition chromatography. | 2020-05-14 |
20200147035 | CANNABINOID COMPOSITIONS AND USES - An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises:
| 2020-05-14 |
20200147036 | METHODS FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE AND/OR LIPODYSTROPHY - The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARy agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD. | 2020-05-14 |
20200147037 | NEW TREATMENT OF BRAIN CANCER - The present invention is directed to a composition comprising palytoxin (PLTX), an analogue or a derivative thereof for use by a non-intracerebral or an intracerebral administration in the prevention and/or in the treatment of a subject suffering from a brain tumor. | 2020-05-14 |
20200147038 | ASSESSING AND TREATING PSYCHEDELIC-RESPONSIVE SUBJECTS - The invention features methods of identifying a subject as being likely to have a positive therapeutic response to a psychedelic agent. Methods of the invention also include administering a psychedelic agent to a subject (e.g., a subject that has been identified as likely to respond positively thereto) to improve mental or physical well-being in the subject (e.g., by treating stress, anxiety, addiction, depression, compulsive behavior, by promoting weight loss, by improving mood, by treating or preventing a condition (e.g., psychological disorder), or by enhancing performance). | 2020-05-14 |
20200147039 | COMPOUNDS USEFUL IN INHIBITING HUMAN TREFOIL FACTOR 3 - Disclosed herein are compounds of Formula I, | 2020-05-14 |
20200147040 | NONRACEMIC MIXTURES AND USES THEREOF - Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride. | 2020-05-14 |
20200147041 | PAROXYSMAL EXTREME PAIN DISORDER TREATMENT - The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof. | 2020-05-14 |
20200147042 | GOSSYPOL ISATIN SCHIFF BASE COMPOUNDS WITH ANTITUMOR ACTIVITIES AND A METHOD OF PREPARING THE SAME - A gossypol isatin Schiff base compound with antitumor activities represented by formula I: | 2020-05-14 |
20200147043 | COMPOSITION COMPRISING A DIINDOLYLMETHANE AND A RETINOID TO TREAT A SKIN CONDITION - Provided is a composition for use in treating a skin condition, the composition comprising:
| 2020-05-14 |
20200147044 | SUNITINIB FORMULATIONS AND METHODS FOR USE THEREOF IN TREATMENT OF GLAUCOMA - Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or other inhibitors of JNK signaling, which bind to DLK. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or reduce neuronal death due to elevated intraocular pressure. Upon administration, the sunitinib or other inhibitor is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity, and which provide much longer release than inhibitor without conjugate. | 2020-05-14 |
20200147045 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINOPATHY AND OTHER OCULAR DISEASES - Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1. | 2020-05-14 |
20200147046 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETINOPATHY AND OTHER OCULAR DISEASES - Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO | 2020-05-14 |
20200147047 | Methods of Treating Resistant Cancers - Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor. | 2020-05-14 |
20200147048 | 5HT AGONISTS FOR TREATING DISORDERS - Provided, inter alia, are methods for treating an epilepsy disorder using a 5HT receptor agonist, or a pharmaceutically acceptable salt thereof. | 2020-05-14 |
20200147049 | 2-IMINOBIOTIN FOR USE IN THE TREATMENT OF BRAIN CELL INJURY - The present disclosure relates to the use of 2-iminobiotin for treating brain cell injury, in particular in adults. The treatment may be used for the treatment of cerebral hypoxia-ischemia and/or reperfusion injury, including one or more symptoms thereof. Provided are methods of treatment comprising administering a therapeutically effective dose of 2-iminobiotin to an individual in need thereof. | 2020-05-14 |
20200147050 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF TYPE IV COLLAGEN DISEASES - Methods of treating Alport syndrome and other diseases associated with a type IV collagen deficiency, and preventing hearing loss associated the same, are provided, comprising administering a compound having structure (I), | 2020-05-14 |
20200147051 | METHODS OF TREATING MIXED DYSLIPIDEMIA AND HYPERTRIGLYCERIDEMIA - The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia. | 2020-05-14 |
20200147052 | THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN OR INSULIN ANALOGS - Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses. | 2020-05-14 |
20200147053 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION - The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder. | 2020-05-14 |
20200147054 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents - The present invention relates to a composition of a CD47-SIRPα blocking agent and one or more anti-cancer agent(s), where the CD47-SIRPα blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRPα blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s). | 2020-05-14 |
20200147055 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE SYNDROME DELIVERING ANTIBIOTIC MACROLIDE - In some embodiments, the present invention is a method of treating dry eye syndrome, comprising: administering a composition to an eye of a mammal in need thereof; wherein the composition is a sustained release composition; wherein the composition is configured to release an effective amount of an active agent per day for a treatment period of at least seven days; and wherein the active agent is Tacrolimus. | 2020-05-14 |
20200147056 | USE OF SIROLIMUS TO TREAT EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA - This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intravitreal sirolimus in subjects that had an inadequate response to prior treatment with an intravitreal anti-vascular endothelial growth factor agent. | 2020-05-14 |
20200147057 | GOSSYPOL 7-N-ISATIN SCHIFF BASE COMPOUNDS WITH ANTITUMOR ACTIVITIES AND A METHOD OF PREPARING THE SAME - A gossypol 7-N-isatin Schiff base compounds compound with antitumor activities represented by formula I: | 2020-05-14 |
20200147058 | KRAS INHIBITOR FOR USE IN TREATING CANCER - Inhibitors of native, non-mutated KRAS for use in preventing and/or treating malignant melanoma and/or hepatocellular carcinoma are disclosed. In addition, a KRAS inhibitor is combined with an inhibitor of another factor of the Ras-Raf-MEK-ERK pathway such as a BRAF inhibitor to reach synergistic inhibitory effects and to overcome tumor cell resistance. The disclosure is further directed to pharmaceutical compositions comprising such inhibitor and a pharmaceutically acceptable agent. | 2020-05-14 |
20200147059 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS - Inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, are useful for the prevention and/or treatment of migraine, including headache, chronic migraine, episodic migraine, medication overuse headache disorder (MOU), migraine without aura, migraine with aura, migraine aura without headache, ocular migraine, vestibular migraine, basilar migraine, hemiplegic migraine, ophthalmoplegic migraine, and tension-type headache (TTH). | 2020-05-14 |
20200147060 | COMPOSITIONS AND METHODS OF TREATING CANCER - The invention provides in certain embodiments a therapeutic regimen comprising (a) an anti-cancer combination of vemurafenib and cobimetinib, or a combination of trametinib and dabrafenib, and (b) a secondary agent comprising L-buthionine-[S,R]-sulfoximine (BSO), or phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof, and chloroquine or hydrochloroquine (HCQ) for the therapeutic treatment of a hyperproliferative disorder. | 2020-05-14 |
20200147061 | HUMAN THERAPEUTIC AGENTS - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 2020-05-14 |
20200147062 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF - The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers. | 2020-05-14 |
20200147063 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR MODULATING HEMATOPOIETIC STEM CELLS AND HEMATOPOIESIS - A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor. | 2020-05-14 |
20200147064 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor - A method involving the administration of a therapeutically effective amount of a leukotriene inhibitor, a pharmaceutically acceptable salt, a pharmaceutically acceptable N-oxide, a pharmaceutically active metabolite, a pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof to a human for reducing a level of pro-inflammatory HDL in the human. Various examples of leukotriene inhibitors, including 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, are disclosed for administration for the reduction of pro-inflammatory HDL in a human. Reduction of pro-inflammatory HDL by the leukotriene inhibitor may include conversion of at least a portion of pro-inflammatory HDL to anti-inflammatory HDL. | 2020-05-14 |
20200147065 | METHODS FOR SHRINKING PITUITARY TUMORS - Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. | 2020-05-14 |
20200147066 | Heteroaryl Sulfonamides and CCR2/CCR9 - Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists. | 2020-05-14 |
20200147067 | Naproxen-Based Non-Steroidal Anti-Inflammatory Drug with Low Gastric Toxicity - A new derivative of naproxen, 3-((S)-2-(6-methoxynaphth-2-yl) propanoyloxy)-4,5-bis (((S)-2-(6-methoxynaphth-2-yl) propanoyloxy)-methyl)-2-methylpyridinium (S)-2-(6-methoxynaphth-2-yl) propanoate has a high anti-inflammatory, analgesic and antipyretic activity, as well as low acute toxicity and gastrotoxicity, it can be used in the pharmaceutical industry, medicine and veterinary. | 2020-05-14 |
20200147068 | USE AND COMPOSITION FOR PROTECTION AGAINST ORGANOPHOSPHORUS POISONING - The present invention relates to compositions comprising an antiemetic, particularly including 5-HT3 antagonist and/or NK-1 antagonist antiemetics, in combination with a choline esterase inhibitor such as an acetylcholine esterase inhibitor and/or a butyrylcholine esterase inhibitor, and methods of using the composition to provide improved protection of subjects at risk of organophosphorus poisoning, or, for the treatment, prevention, or alleviation/reduction of toxicity from an organophosphorus compound, by enabling the use of a highly protective daily dose of the choline esterase inhibitor without the typical adverse effects. | 2020-05-14 |
20200147069 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes - Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a tetrahydrocarbazolamine compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided. | 2020-05-14 |
20200147070 | INDUCING PHOSPHOLIPIDOSIS FOR ENHANCING THERAPEUTIC EFFICACY - A method of enhancing the efficacy of a therapeutic compound, the method comprising administering an effective amount of a phospholipidosis (PL)-inducing compound (or compounds) to a patient in need of a therapeutic compound for a disorder, whereby PL is induced in the patient; and administering the therapeutic compound to the patient. | 2020-05-14 |
20200147071 | TOPICAL FORMULATIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND USES THEREOF - Disclosed herein are topical compositions of 5-α reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-α reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects. | 2020-05-14 |
20200147072 | Folate Receptor Binding Conjugates of Antifolates - Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating such diseases are also described. | 2020-05-14 |
20200147073 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT CERVICAL CANCER - Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin. | 2020-05-14 |
20200147074 | MANUFACTURING PROCESS OF FORMULATION HAVING IMPROVED CONTENT UNIFORMITY - The present invention offers the manufacturing method of the solid formulation wherein the standard deviation of the active ingredient content in the solid formulation becomes 5% or less by mixing the excipients which have a median particle size of 15 or more times, preferably 20 times or more to the median particle size of an active ingredient. | 2020-05-14 |
20200147075 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2020-05-14 |
20200147076 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME - There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases. | 2020-05-14 |
20200147077 | Methods of Treating Ischemic Disease by Administering an ATR Kinase Inhibitor - A method of treating a subject suffering from an ischemic disease associated with Ca | 2020-05-14 |
20200147078 | THERANOSTIC AGENTS - A theranostic agent can be used in both photoacoustic imaging (PAI) and photothermal therapy (PTT) applications. The theranostic agent can include a small molecule, organic compound with absorption in the near-infrared (NIR) interrogation window (700-900 nm). The compound can be a biocompatible organic nanoparticle (ONP). The theranostic agent can be effectively used in PAI and PAI-guided PTT applications. The theranostic agent can be administered to a patient to locate a tumor site in the patient using in vivo imaging techniques. Once the tumor site has been determined, the tumor site can be irradiated with near-infrared light to stop or inhibit the growth of the tumor. | 2020-05-14 |
20200147079 | REGIMENS FOR TREATING HIV INFECTIONS AND AIDS - A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine. | 2020-05-14 |
20200147080 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH - The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer). | 2020-05-14 |
20200147081 | Use of Kinase Inhibitors to Manage Tuberculosis and Other Infectious Diseases - This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with | 2020-05-14 |
20200147082 | METHODS OF TREATING NEUROEPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS - Applicant discloses methods for treating a glucocorticoid receptor positive (GR | 2020-05-14 |
20200147083 | SMALL MOLECULE MODULATORS OF HUMAN STING - The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. | 2020-05-14 |
20200147084 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY - Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections. | 2020-05-14 |
20200147085 | COMPOSITIONS AND METHODS FOR TREATMENT OF PSYCHIATRIC DISORDERS - Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain L-methionine. | 2020-05-14 |
20200147086 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS - In one aspect, the present disclosure provides methods of treating a bacterial infection using an inhibitor of the nucleotidyltransferase superfamily enzyme. In some embodiments, the compounds have one of the following formulas (I), (II), (III), or (IV) wherein R | 2020-05-14 |
20200147087 | METHODS FOR TREATING HUNTINGTON'S DISEASE - The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): | 2020-05-14 |
20200147088 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof - Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins. | 2020-05-14 |
20200147089 | PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB - The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability. | 2020-05-14 |
20200147090 | METHODS OF SCREENING BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS - The invention discloses methods for screening out of a BRaf inhibitor population, suitable BRaf inhibitors as candidates for clinical development of drugs for treating and/or preventing cutaneous reaction caused by treatment with EGFR inhibitor and/or PI3K inhibitors. | 2020-05-14 |
20200147091 | COMPOSITIONS FOR MODULATING PD-1 SIGNAL TRANSDUCTION - Several compounds have been discovered that modulate signal transduction through the PD-1 receptor. In certain embodiments, the compounds promote or induce an activating signal through the PD-1 receptor that activates a T cell. The compounds can bind to PD-1 and inhibit or prevent ligands from binding to PD-1 and thereby suppress inhibitory signal transduction through the PD-1 receptor. | 2020-05-14 |
20200147092 | REGIMENS FOR TREATING HIV INFECTIONS AND AIDS - Disclosed are methods for treating human immunodeficiency virus (HIV) or AIDS in a human subject using only two antiretroviral drugs, the subject being virologically suppressed and having previously followed a treatment regimen including at least three antiretroviral drugs. | 2020-05-14 |
20200147093 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA - Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being. | 2020-05-14 |
20200147094 | USE OF REBOXETINE TO TREAT NARCOLEPSY - Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being. | 2020-05-14 |
20200147095 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA - Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being. | 2020-05-14 |
20200147096 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA - Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being. | 2020-05-14 |
20200147097 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES - The present invention describes the use of a NK1-antagonist, in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone. | 2020-05-14 |
20200147099 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY - The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer. | 2020-05-14 |
20200147100 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME - Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like. | 2020-05-14 |
20200147101 | USE OF AMINOALKYLBENZOTHIAZEPINE DERIVATIVES - The present disclosure relates to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease or dyslipidemia comprising an aminoalkylbenzothiazepine derivative or a pharmaceutically acceptable salt thereof as an active ingredient. | 2020-05-14 |
20200147102 | FORMULATIONS OF LIXIVAPTAN FOR THE TREATMENT OF POLYCYSTIC DISEASE - Formulations of lixivaptan, and methods of using the same, are provided for the treatment of polycystic disease. | 2020-05-14 |